


quantification & biomarker studies



 $1000\ {\rm cases},\ {\rm DATSCAN}\ [{\rm SPECT}],\ 7{\rm -classes}\ {\rm clinical}\ {\rm visual}\ {\rm reading}$


4 independent quantification methods

Dopaminergic imaging

DATSCAN [SPECT]

Target: neurodegeneration linked to Parkinson's disease and related symptoms

Collaboration with: Osp. Univ. di Padova (PD)



doi:10.1093/brain/awaa365

BRAIN 2020: Page I of I0

aPutamenAs aCaudateMAH aPCratio.


aPCratio_R aCaudateLAH


Constipation

Hyposmia

Dopaminergic imaging and clinical predictors for phenoconversion of **REM** sleep behaviour disorder

Dario Arnaldi,^{1,2} Andrea Chincarini,³ Michele T. Hu,⁴ © Karel Sonka,⁵ Bra Tomoyuki Miyamoto,⁷ Monica Puligheddu,⁸ Valérie Cochen De Cock,⁹ Michele Terzaghi,^{10,11} Giuseppe Plazzi,^{12,13} Naoko Tachibana,¹⁴ Silvia Mo Michal Rolinski,^{4,17} Petr Dusek,⁵ Val Lowe,¹⁸ Masayuki Miyamoto,¹⁹ Michi ^aPutamentAH Delphine de Verbizier,²⁰ Irene Bossert,²¹ Elena Antelmi,^{12,22} Riccardo M [©] Thomas R. Barber⁴ Jiří Tirnka,²³ Toji Miyagawa,⁶ Alessandra Serra,²⁴ Fa [©] Matteo Bauckneht,^{15,16} Kevin M. Bradley,²⁵ [©] David Zogala,²³ Daniel R. ^{Acudateks}





DATSCAN + NPSY + Clinics

in collaboration with: the international group of RBD

SPECT quantification analysis + ranking the most significant predictors of phenoconversion + survival analysis up to 9 years



NeuroImage: Clinical Volume 23, 2019, 101846



Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC)

A. Chincarini ª 🛠 🖾, E. Peira ^{a, d}, S. Morbelli ^{b, c}, M. Pardini ^{c, d}, M. Bauckneht ^c, J. Arbizu ^c, M. Castelo-Branco ^f, K.A.

Büsi Original Article | Published: 25 January 2020 Gari

A kinetics-based approach to amyloid PET semiquantification

A. Chincarini 🖂, E. Peira, M. Corosu, S. Morbelli, M. Bauckneht, S. Capitanio, M. Pardini, D. Arnaldi, C. Vellani, D. D'Ambrosio, V. Garibotto, F. Assal, B. Paghera, G. Savelli, A. Stefanelli, U. P. Guerra & F. Nobili

European Journal of Nuclear Medicine and Molecular Imaging (2020) | Cite this article

Emerging topics and practical aspects for an appropriate use of amyloid PET in the current Italian context.

Nobili F¹^{SE}, Cagnin A², Calcagni ML³, Chincarini A⁴, Guerra UP⁵, Morbelli S⁶^{OD}, Padovani A⁷, Paghera B⁸, Pappatà S⁹, Parnetti L¹⁰, Sestini S¹¹, Schillaci O¹² *Journal of Nuclear Medicine and Molecular Imaging*


Amyloid imaging

latest papers on quantification, clinical validation, patterns

in collaboration with: italian IRCCS, EADC, AIM, EANM

(INFN CSN5, 2019






SUVr-independent evaluation of brain amyloidosis, Chincarini et. al, Journal of Alzheimer's Disease, Vol. 54-4 (2016)

Approaches to semi-quantification: beyond SUVr in amyloid imaging, European Conference on Clinical Neuroimaging, Roma (2016)

Semi-quantification and grading of amyloid PET, Chincarini et. al, Neuroimage Clinical, (2019)

> bias on higher intensities




Quantification and ranking in amyloid-PET, R. Gianeri, Master in


TDr



REQUIREMENT: needs the early scan (0-5' from injection)








5. 2019


* Chincarini et al. Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC). NeuroIm. Clin. 2019


Clinical correlates



under review at Journal of Alzheimer's Disease

5.2019






Neuropsychology

Innovative use of NPSY tests in the discrimination of Alzheimer concomitant pathologies (10 clinical cohorts)

multivariate KDE + odds ratio analysis

in collaboration with: IRCCS GE

paper submitted to Alzh. res. & therapy [IF 6.1]






Towards alternative tests for brain amyloidosis



Aknowledgements to: Prof. Flavio Nobili Doc. Francesco Famà Prof. Silvia Morbelli



Candidate: Gloria Pedemonte

Supervisor: Prof. Andrea Chincarini

EEG analysis

AMYLOID


Wilcoxon rank sum test pv = 0.000

0.5

EEG combined featur

DL + quantification exploratory model (autoencoders) to link EEG patterns to amyloid & FDG impairment

in collaboration with: IRCCS GE paper under preparation



technology transfer

DORIAN technologies



Founders:

Andrea Chincarini Francesco Sensi Paolo Bosco Mirko Corosu Enrico Peira Ruben Gianeri

Med advisors:

Flavio Nobili Silvia Morbelli

Diego Cecchin Davide Poggiali

Stelvio Sestini Luca Fedeli

your key to better data analysis

Andrea Chincarini

INFN

mission: NM in neurology

clinical practice

medical research

medical training

pharmaceutical trials

today

tomorrow

personalized medicine

screening

certification as medical device To **develop** and distribute **reliable AI-driven analyses** to improve **diagnostic impact**, **reliability** and clinical **confidence**.

Two analysis pipelines currently available:

- DAT SPECT (datscan & striascan)
- amyloid-PET (all 3 fluorinated tracers)

Future efforts to include:

- FDG
- FDOPA
- tau-PET
- T1-MRI atrophy pattern
- T2-MRI WM lesions


We provide a comprehensive learning environment to approach automatic analysis of amyloid PET in a typical clinical setting

We help to write a more informed diagnosis report

we help reducing the diagnostic error

We provide on-demand continuous medical training on specific pathology

We comply with NM societies requirements



SN25*

Training on amyPET

[2017 -]

AIMN national school of Nuclear Medicine in Neurology (Pesaro, September 2006-)